HomeAI · summaries
Storia in 3 fonti
Novartis stock rises after MS drug remibrutinib trial results
The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both studies
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis says MS pill succeeds in two large studies
Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
- ·
milanofinanza.it
Novartis, Remibrutinib centra gli obiettivi sulla sclerosi multipla. In secondo piano lo stop a otto studi su Rap-cel | MilanoFinanza News
Ubs stima una probabilità del 50% di successo per il farmaco sperimentale Remibrutinib con vendite al picco previste a 4,5 miliardi di dollari. Nominato Federico Mambretti Country…
